Popular articles
VioQuest Pharmaceuticals Appoints an Industry Veteran as
Chief Medical Officer
BASKING RIDGE, NJ –March 15, 2006– VioQuest Pharmaceuticals, Inc. ( VQPH ) has named Pamela Harris, MD, to the role of chief medical officer. Dr. Harris brings to VioQuest extensive pharmaceutical industry knowledge and experience in clinical development and the regulatory approval process, particularly in the area of oncology.
Prior to joining VioQuest, Dr. Harris served as chief medical officer at Callisto Pharmaceuticals, Inc. She was previously senior medical director for Pfizer, where she was responsible for U.S. development of Aromasin, an aromatase inhibitor for breast cancer, and Epirubicin, an anthracycline for adjuvant chemotherapy of breast cancer. Prior to
Pfizer, Dr. Harris served in different capacities in clinical research focused mainly in oncology drug research at Hoffman-La Roche Pharmaceuticals, Wyeth Pharmaceuticals, U.S. Bioscience, Inc, and a clinical practice focused on clinical investigation of new drugs.
"Pamela's extensive experience in the clinical development of new cancer drugs, combined with her unique insight on bringing drugs through the regulatory process, will help round out VioQuest's leadership team and bring the clinical depth which is critical for the success of the Company," said Daniel Greenleaf, VioQuest's chief executive officer. "With her considerable background in oncology, both as a practicing physician and through industry experience in the
world-wide clinical development of cancer therapeutics, we feel exceptionally fortunate to have her as our Chief Medical Officer of VioQuest."
Dr. Harris, who is board certified in internal medicine and medical oncology, received her M.D. degree from the Ohio State University College of Medicine, Columbus, Ohio. This was followed by an internship and residency at the Washington Hospital, Washington, DC. Dr. Harris has had fellowships at Memorial Sloan Kettering Cancer
Center, Georgetown University – Lombardi Cancer Center, George Washington University Hospital, and the Jackson Memorial Cancer Center.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc. acquires, develops and commercializes targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. A leader in personalized therapeutics, VioQuest has two
targeted therapeutics in clinic trials: VQD-001, an inhibitor of
specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers, and VQD-002, which has been shown to inhibit the phosphorylation of Akt seen in abnormal levels in breast, ovarian, colorectal, pancreatic and liquid cancers.
VioQuest's subsidiary Chiral Quest, a pioneer in asymmetric
chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. For more information please visit www.vioquestpharm.com.
--------------------------------------------------------------------------------------------------
Alba Spectrum popular articles series: FAQ, Reviews, Introductions, Product Selections,
Advises, Definitions, online marketing
We are serving wholesale & retail customers in
Illinois, California, Texas, Wisconsin, New York, Washington, Ohio, Michigan,
Indiana, Arizona, New Mexico, Louisiana, Florida, Georgia, Minnesota, Utah, Virginia, Georgia, Hawaii,
Iowa, Colorado, Ontario, Quebec, Alberta, British Columbia. We also serve customer
internationally in New Zealand, Europe: UK, France, Poland, Italy, Germany, Russia, India, Byrma, Thailand, Holland, Denmark, Sweden, Norway, Indonesia, Austria, New Zealand, Pakistan, Afghanistan, Iran, Spain, Argentina, Brazil, Chile, Uruguay, Paraguay, Peru, Equador, Colombia, Venezuela, Panama, Costa Rica, Canada, South Africa, Nigeria,
Portugal, Greece, Turkey, Asia: India, China, Philippines, South Korea, plus business metros: Chicago, Los Angeles, Phoenix, Boston, Atlanta, Minneapolis, Fargo, Seattle, Miami, Orlando, Detroit, Buffalo, Toronto, Paris, London, Montreal, Denver, Warsaw, Berlin, Prague, Rome, Karachi, Sao Paulo, Rio de Janeiro, Moscow, Buenos Aires, Dehli, Mumbai, Beigin, Cairo, San Francisco, Fremont, Naperville, Oakland, Mellburn, Sidney, Sent Petersburg, Tampa, New Orleans, Houston, Dallas, Mexico City, Bogota, Caracas, Lima, Salvador, Recife, Sao Paulo, Rio de Janeiro, Brasilia, Curitiba, Goiania. http://www.albaspectrum.com